NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam. Both ...
Tegsedi is produced by Ionis’ subsidiary Akcea, and is also approved in the European Union. In hATTR amyloidosis, transthyretin (TTR) protein misfolds and accumulates as amyloid deposits ...
Pharmaceutical Technology on MSN20d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathyAstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback